Quest Diagnostics completes acquisition of PathAI Diagnostics

Quest Diagnostics announced that it has completed the acquisition of PathAI Diagnostics, PathAI’s anatomic and digital pathology laboratory services company.

The acquisition of PathAI’s laboratory assets was initiated and announced in early May.

Under the terms of the acquisition, PathAI Diagnostics’ digitized Memphis laboratory has been renamed AmeriPath and will operate as a national research and development center for artificial intelligence (AI) and digital solutions and research for Quest’s specialty pathology companies, AmeriPath and Dermpath Diagnostics.

PathAI, which remains an independent company, will maintain a separate research laboratory at the same Memphis location to support its biopharmaceutical customers, according to the companies’ statements.

Additionally, PathAI and Quest have entered into agreements to further advance the implementation of artificial intelligence and digital pathology. Specifically, Quest will license PathAI’s AISight digital pathology image management system to its U.S. pathology laboratories and customer facilities. Quest, in turn, is the preferred laboratory services partner for PathAI’s biopharmaceutical customers. The companies added that PathAI and Quest may collaborate to develop artificial intelligence algorithms for research and clinical applications.